To include your compound in the COVID-19 Resource Center, submit it here.

Kala falls on mixed data for dry eye candidate

Kala Pharmaceuticals Inc. (NASDAQ:KALA) lost $5.08 (29%) to $12.26 on Friday after reporting mixed data from the Phase III STRIDE 1 and STRIDE 2 trials of KPI-121

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE